[go: up one dir, main page]

DE69432573D1 - Inhibitoren des Endothelin konvertierenden Enzyms - Google Patents

Inhibitoren des Endothelin konvertierenden Enzyms

Info

Publication number
DE69432573D1
DE69432573D1 DE69432573T DE69432573T DE69432573D1 DE 69432573 D1 DE69432573 D1 DE 69432573D1 DE 69432573 T DE69432573 T DE 69432573T DE 69432573 T DE69432573 T DE 69432573T DE 69432573 D1 DE69432573 D1 DE 69432573D1
Authority
DE
Germany
Prior art keywords
converting enzyme
endothelin converting
enzyme inhibitors
compounds
endothelin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69432573T
Other languages
English (en)
Other versions
DE69432573T2 (de
Inventor
Johann Jakob Leban
Douglas Byron Sherman
James Frederick Sigafoos
Andreas Spaltenstein
Osvaldo Humberto Viveros
David Chi-Cheong Wan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of DE69432573D1 publication Critical patent/DE69432573D1/de
Application granted granted Critical
Publication of DE69432573T2 publication Critical patent/DE69432573T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE69432573T 1993-01-04 1994-01-04 Inhibitoren des Endothelin konvertierenden Enzyms Expired - Fee Related DE69432573T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939300048A GB9300048D0 (en) 1993-01-04 1993-01-04 Endothelin converting enzyme inhibitors
GB9300048 1993-01-04

Publications (2)

Publication Number Publication Date
DE69432573D1 true DE69432573D1 (de) 2003-05-28
DE69432573T2 DE69432573T2 (de) 2004-01-08

Family

ID=10728286

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432573T Expired - Fee Related DE69432573T2 (de) 1993-01-04 1994-01-04 Inhibitoren des Endothelin konvertierenden Enzyms

Country Status (10)

Country Link
US (1) US6235717B1 (de)
EP (2) EP1029869B1 (de)
JP (1) JP3529381B2 (de)
AT (1) ATE238343T1 (de)
AU (1) AU5820294A (de)
DE (1) DE69432573T2 (de)
ES (1) ES2193919T3 (de)
GB (1) GB9300048D0 (de)
WO (1) WO1994015956A1 (de)
ZA (1) ZA948B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU673731B2 (en) * 1993-06-03 1996-11-21 Banyu Pharmaceutical Co., Ltd. Novel endothelin antagonistic peptide
EP0731107A1 (de) * 1995-02-13 1996-09-11 Takeda Chemical Industries, Ltd. Herstellung von Aldehyd-Derivaten
DE19745146A1 (de) 1997-10-14 1999-04-15 Basf Ag Neue pharmazeutisch wirksame Verbindungen, ihre Herstellung und Verwendung
US6649593B1 (en) * 1999-10-13 2003-11-18 Tularik Inc. Modulators of SREBP processing
ES2275675T3 (es) * 2000-03-23 2007-06-16 Elan Pharmaceuticals, Inc. Compuestos y metodos para tratar la enfermedad de alzheimer.
AU2002222933A1 (en) * 2000-07-13 2002-01-30 Millennium Pharamaceuticals, Inc. Inhibitors of factor xa
US7842727B2 (en) * 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
EP1511477A4 (de) * 2002-05-22 2008-04-09 Errant Gene Therapeutics Llc Histondeacetylase-hemmer auf basis von alpha-ketoepoxid-verbindungen
EP1511729A4 (de) * 2002-05-22 2006-09-06 Errant Gene Therapeutics Llc Auf alphachalcogenmethylcarbonylverbindungen basierende histondeacetylaseinhibitoren
DE602005025750D1 (de) 2004-04-15 2011-02-17 Proteolix Inc Verbindungen zur proteasomenzymhemmung
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
CN101014612B (zh) 2004-05-10 2014-11-26 欧尼斯治疗公司 用于酶抑制的化合物
EP1752467A1 (de) * 2005-08-10 2007-02-14 4Sc Ag Krebszellen-, t-Zellen- und Keratinocyte-Proliferation-Inhibitoren
US7531517B2 (en) * 2005-08-10 2009-05-12 4Sc Ag Inhibitors of cancer cell, T-cell and keratinocyte proliferation
KR101274417B1 (ko) 2005-11-09 2013-06-17 프로테올릭스, 인코퍼레이티드 효소 저해를 위한 화합물
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
SG185994A1 (en) 2007-10-04 2012-12-28 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
EP2349313A4 (de) 2008-10-21 2012-08-29 Onyx Therapeutics Inc Kombinationstherapie mit peptidepoxyketonen
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
EP2498793B1 (de) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib zur verwendung in der metastasensuppression
EA201290844A1 (ru) 2010-03-01 2013-03-29 Оникс Терапьютикс, Инк. Соединения для ингибирования иммунопротеасом
BR112012025264A2 (pt) 2010-04-07 2019-09-24 Onyx Therapeutics Inc inibidor de imunoproteassoma de e´poxicetona peptídica cristalina.
UY34897A (es) 2012-07-09 2014-01-31 Onyx Therapeutics Inc Profarmacos de inhibidores peptidicos de expoxi cetona proteasa

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL90218A0 (en) * 1988-05-13 1989-12-15 Abbott Lab Retroviral protease inhibitors
CA2043741C (en) * 1990-06-07 2003-04-01 Kiyofumi Ishikawa Endothelin antagonistic peptide derivatives
EP0472077A3 (en) 1990-08-24 1993-03-31 Bayer Ag Phosphonate containing hydroxyethylamin- and norstatin-type pseudopeptides
US5444042A (en) * 1990-12-28 1995-08-22 Cortex Pharmaceuticals Method of treatment of neurodegeneration with calpain inhibitors
US5382569A (en) * 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
JPH05105698A (ja) * 1991-06-13 1993-04-27 Takeda Chem Ind Ltd ホスホン酸誘導体、その製造法および用途
US5504070A (en) * 1991-12-05 1996-04-02 Berlex Laboratories, Inc. Inhibitors of the conversion of big endothelin to endothelin
US5610297A (en) * 1991-12-27 1997-03-11 Georgia Tech Research Corp. Peptides ketoamides
JP2848232B2 (ja) * 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
US5607831A (en) * 1993-03-25 1997-03-04 The United States Of America As Represented By The Department Of Health And Human Services In vitro methods for assessing the susceptibility of HIV-1-infected individuals to cysteine protease-mediated activation-induced programmed cell death
WO1994028012A1 (en) * 1993-05-28 1994-12-08 Warner-Lambert Company Hydroxamate inhibitors of endothelin converting enzyme
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein

Also Published As

Publication number Publication date
GB9300048D0 (en) 1993-03-03
AU5820294A (en) 1994-08-15
ES2193919T3 (es) 2003-11-16
JP3529381B2 (ja) 2004-05-24
ATE238343T1 (de) 2003-05-15
JPH08506569A (ja) 1996-07-16
ZA948B (en) 1995-07-03
US6235717B1 (en) 2001-05-22
EP0677059A1 (de) 1995-10-18
WO1994015956A1 (en) 1994-07-21
DE69432573T2 (de) 2004-01-08
EP1029869B1 (de) 2003-04-23
EP1029869A1 (de) 2000-08-23

Similar Documents

Publication Publication Date Title
ATE238343T1 (de) Inhibitoren des endothelin konvertierenden enzyms
MY113489A (en) Reversible protease inhibitors
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
MY131388A (en) Inhibitors of hiv protease useful for the treatment of aids.
GB2288732B (en) Pharmaceutical compositions
ZA885824B (en) Novel antidepressants
CA2289851A1 (en) Compounds and methods for the inhibition of the expression of vcam-1
BR9908280A (pt) Inibidores de enzimas de fosfolipase
TW225532B (de)
MX9703564A (es) Inhibidores de proteasa multicatalitica.
ATE214610T1 (de) Neuartige pharmazeutische verwendungen von krill- enzymen
TW268937B (de)
AP1696A (en) Agrochemical formulations comprising ALS inhibitors.
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
AU7296696A (en) Deodorising formulations containing cationic biopolymers, aluminium chlorhydrate and esterase inhibitors
NO955288L (no) Skvalen-syntetase inhibitorer
ATE305517T1 (de) Neurotrypsin
ES2164911T3 (es) Composicion farmaceutica que contiene inhibidores de interferon gamma.
ATE197716T1 (de) Waschmittelenzyme
ATE223427T1 (de) Modifizierte kojibioside analoge
AU1516892A (en) Novel 2-mercaptomethylene-tetrahydronaphthalene and indane-2-carboxamide derivatives as enkephalinase inhibitors
DK0828483T3 (da) Anvendelse af tropolonderivater som inhibitorer af enzymet inositolmonophosphatase
NZ209250A (en) Alpha-allenic-alpha-amino acids and pharmaceutical compositions
RU93055684A (ru) Соединения, ингибирующие вич-протеазу, способ их получения, фармацевтическая композиция, промежуточный продукт

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee